NeuroMetrix (NURO) Reports Q1 Loss of $0.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeuroMetrix Reports Q1 2015 Financial Results and Highlights
April 21, 2015 7:00 AM EDTDiabetes Product Revenue Growth, Preparation for Quell Launch
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the Company) (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2015.
The Company operates in two primary markets - wearable therapeutic technology and point-of-care tests. It is preparing for the launch of its newest product, Quell, an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The device is designed for users with conditions such as diabetic nerve pain, low back and leg pain,... More
